| Drug General Information |
| Drug ID |
D08QGT
|
| Former ID |
DCL001088
|
| Drug Name |
GDC0941
|
| Synonyms |
GD9; GDC 0941; GDC-0941; GDC-0941, GDC0941; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine
|
| Drug Type |
Small molecular drug
|
| Indication |
Advanced solid tumor; Non-hodgkin's lymphoma [ICD9: 140-199, 200, 202, 202.8, 210-229; ICD10:C00-C75, C7A, C7B, C81-C86, C82-C85, D10-D36, D3A]
|
Phase 2 |
[1],
[2]
|
|---|
| Company |
Genentech
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H27N7O3S2
|
| InChI |
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
|
| InChIKey |
LHNIIDJUOCFXAP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
29212926, 49786957, 54248659, 56374172, 85756855, 87225804, 99436963, 103605815, 103905592, 124756973, 124898667, 125163778, 126583893, 126644602, 126666983, 126724369, 131331324, 131465130, 134339479, 134964407, 135256495, 135264679, 135626907, 135631960, 135684972, 135685275, 135685279, 135685283, 135686120, 135686121, 135686142, 135686143, 135698921, 135727434, 136920330, 137244615, 137275833, 140991552, 143498831, 144116006, 152105922, 152240252, 152258791, 152344010, 160644992, 160647642, 160778578, 160826754, 162011380, 162037413
|
| Target and Pathway |
| Target(s) |
Phosphoinositide 3 kinase |
Target Info |
Inhibitor |
[3],
[4]
|
|---|
|
KEGG Pathway
|
Inositol phosphate metabolism
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
Jak-STAT signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
Carbohydrate digestion and absorption
|
|
Bacterial invasion of epithelial cells
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
PathWhiz Pathway
|
Inositol Metabolism
|
|
Phosphatidylinositol Phosphate Metabolism
|
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
PI3K Cascade
|
|
GPVI-mediated activation cascade
|
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
PI3K events in ERBB4 signaling
|
|
PIP3 activates AKT signaling
|
|
GAB1 signalosome
|
|
PI3K events in ERBB2 signaling
|
|
PI3K/AKT activation
|
|
Role of phospholipids in phagocytosis
|
|
Tie2 Signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
Nephrin interactions
|
|
Costimulation by the CD28 family
|
|
CD28 dependent PI3K/Akt signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
VEGFA-VEGFR2 Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Constitutive Signaling by EGFRvIII
|
|
PI-3K cascade:FGFR1
|
|
PI-3K cascade:FGFR2
|
|
PI-3K cascade:FGFR3
|
|
PI-3K cascade:FGFR4
|
|
Interleukin receptor SHC signaling
|
|
Regulation of signaling by CBL
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
Insulin Signaling
|
|
IL-4 Signaling Pathway
|
|
Copper homeostasis
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Transcriptional activation by NRF2
|
|
IL1 and megakaryotyces in obesity
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Fc epsilon receptor (FCERI) signaling
|
|
PI Metabolism
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
PIP3 activates AKT signaling
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
TSH signaling pathway
|
|
SREBP signalling
|
|
TCR signaling
|
|
Signaling by PDGF
|
|
Signaling by Insulin receptor
|
|
Signaling by FGFR
|
|
Signaling by EGFR
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Nephrin interactions
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
GPVI-mediated activation cascade
|
|
GPCR downstream signaling
|
|
Costimulation by the CD28 family
|
|
Cell surface interactions at the vascular wall
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Angiogenesis
|
|
Regulation of toll-like receptor signaling pathway
|
|
AMPK Signaling
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5682). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027517) |
|---|
| REF 3 | The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. |
|---|
| REF 4 | Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. |
|---|
